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Thea Magrone* and Emilio JirilloAbstract
Intestinal microbiota and gut immune systems interact each other, maintaining a condition of homeostasis in the
context of the intestinal habitat. However, both systems undergo modifications in elderly, thus accounting for a low
grade inflammatory status which, in turn, may evolve toward more severe pathological conditions such as
inflammatory bowel disease and colon rectal cancer. In addition, in western societies dietary habits may negatively
influence the microbiota composition, also altering gut immune response which is per se impaired in elderly. In
order to prevent the outcome of aged-related disease, supplementation of nutraceuticals able to correct
abnormalities of both immune system and microbiota has become more frequent than in the past. In this respect,
a better identification of components of the aged microbiota as well as a deeper analysis of gut mucosal immunity
function should be pursued.
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The intestinal microbiota is mostly confined in the colon
where resides 1.5 Kg of microbes that is equal to about
1014 microorganims [1]. Human microbiota represents a
“superorganism” possessing more genes than the human
genome [2]. It undergoes individual variations in its
composition and, in the same individual, variations in
the different segments of the bowel have been reported
[3]. Moreover, the microbiota of the mucosa seems to
differ from that of the lumen and not always a direct inter-
action between microbiota and epithelial cells does occur
[4]. Actually, two major phyla have been identified in the
animal and human microbiota, such as Bacteroidetes
(Gram-negative bacteria) and Firmicutes (Gram-positive
bacteria). However, Actinobacteria and Protobacteria can
predominantly colonize the intestine in some people [5,6].
In the context of the gut associated lymphoid tissue
(GALT), enterocytes or intestinal epithelial cells (IECs)
represent the first barrier against invading microorgan-
isms either secreting mucin or defensins (a class of anti-
microbial peptides) or sensing pathogens via Toll-like* Correspondence: thea.magrone@libero.it
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distribution, and reproduction in any mediumreceptors (TLRs) [7]. Furthermore, microfolding (M)
cells, specialized IEC, are able to sample microbial anti-
gens and transfer them to lamina propria (LP) immune
cells [e.g., dendritic cells (DCs)] [8]. In turn, DCs act as
presenting antigen cells (APCs), thus triggering both
harmful and protective responses in the host [9]. DCs in
the presence of a milieu enriched in interleukin (IL)-6,
IL-1β and transforming growth factor (TGF)-β are able
to polarize the immune response towards T helper (h)17
cells which, in turn, release IL-17A, IL-17 F, IL-21 and
IL-22, thus becoming inflammatory in the presence of
IL-23 [10]. This immune pathway is mainly activated in
the course of inflammatory bowel disease (IBD).
On the other hand, CD103+ cells are tolerogenic
and in the presence of IL-10, TGF-β, thymic stromal
lymphopoietin and vasoactive intestinal peptide induce T
regulatory (Treg) cells [11]. These CD4 +CD25 + FoxP3+
cells release IL-10 in the bowel, counteracting the activity
of Th17 cells [12]. This tolerogenic anti-inflammatory
activity is favored by retinoic acid (RA), a metabolite
of vitamin A, produced by CD103+ tolerogenic DCs [13].
Of note, RA seems to directly interfere with Th17
polarization. In the context of intestinal mucosa, secretoryentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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to mucosal surfaces and neutralize toxins.
Regulation of the intestinal immune homeostasis by
the microbiota is illustrated in Figure 1.
In aged GALT, a marked multiple impairment of the
immune response has been reported as evidenced by
several studies conducted in animal models [14]. Major
alterations are represented by [15]:
1. Reduced secretion of mucus and α-defensin;
2. Easy entry of pathogens into the mucosal layers and
generation of a low grade inflammatory response
(the so-called “inflamm-ageing”) [16] with Th1, Th2
and Th17 cell polarization.
This condition of inflamm-ageing [16] is perpetuated
by overgrowth of intestinal pathobionts.
Interactions between intestinal microbiota
and immune system
Microbiota and immune cells actively interact within the
gut [17]. Evidence has been provided that Bacteroides
fragilis induces production of IL-10 by Treg cells viaFigure 1 Immune homeostatis maintained by the intestinal
microbiota. The equilibrium between Bacteroidetes and Firmicutes
leads to the activation of T regulatory cells with production of the
anti-inflammatory cytokine IL-10. On the other hand, release of IL-17
by Th17 cells is reduced.recognition of the polysaccharide A by TLR-2 [18]. In
addition, lactobacilli and bifidobacteria play a tolerogenic
role, rendering DCs less undifferentiated [19]. Con-
versely, segmented filamentous bacteria (SFB), compo-
nent of the animal microbiota, are able to induce
production of IL-17 from Th17 cells in mice [20]. There-
fore, a fine balance is required in the daily interplay be-
tween microbiota and innate and adaptive immune cells
to avoid noxious reactions to the host. According to the
two-hit model [21] alteration of the microbiota triggers
IL-6 production by lamina propria DCs, thus leading to
activation of T0 cells. Differentiation of T0 cells into
Th1 cells and Th17 cells creates an inflammatory milieu
which culminates in colitis (Figure 2).
Studies on the aged intestinal microbiota have led to
conflicting results. A decline of bifidobacteria and lacto-
bacilli has been reported in the elderly with an increase
of Bacteroides and facultative anaerobes [22,23]. In con-
trast, others reported higher levels of Ruminococcus andFigure 2 The two-hit model in experimental colitis. Alteration of
the microbiota leads to the activation of DCs which produce IL-6
(first hit). In turn, IL-6 activates T0 cells which differentiate into Th1
cells and Th17 cells, respectively. This polarization of the immune
response generates production of inflammatory cytokines
(second hit).
Figure 3 Effects of altered microbiota in the intestinal immune
response in elderly people. Even if data on the aged microbiota
are still controversial, in some cases increase of Firmicutes and
decrease of Bacteroidetes may lead to a switch of the immune
response towards an inflammatory profile with activation of
Th17 cells.
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higher levels of bifidobacteria in comparison with the
younger counterpart [25]. Finally, no differences between
aged and younger individuals have been reported by
others except for higher numbers of aerobes in elderly
[26]. Also differences in aged microbiota were found de-
pending on the country examined. In this respect, in a
small population of aged Italian subjects an unchanged
level of Bacteroidetes and an increase in Faecalibacterium
spp. were observed [27]. Viceversa in a large cohort of
Irish elderly people Bacteroidetes and Faecalibacterium
spp. remarkably increased [22]. In the above mentioned
group of Italian people no differences in microbiota were
found when young adults (30 yrs old) and elderly (70 yrs
old) were compared. Conversely, in the same group, cen-
tenarians exhibited a different composition of their micro-
biota. While Bacteroidetes and Firmicutes were still
present with levels comparable to those of younger adults,
a decrease of Clostridium cluster XIVa, an increase in
bacilli and rearrangement of Clostridium cluster IV were
reported [27]. In addition, in centenarians the observed in-
crease in Proteobacteria, the so-called “pathobionts”, may
explain the high frequency of infections once these bac-
teria have escaped from the host immune response [28].
Microbiota components account for the production of
short chain fatty acids (SCFA) and, in particular butyrate,
acetate and propionate. SCFA are endowed with anti-
inflammatory (inhibition of NF-κB) and anti-neoplastic
activities, also exerting a protective function in favor of
intestinal epithelia [29]. In fact, butyrate has been shown
to provide energy to the intestinal epithelium, as suggested
by epithelial atrophy and inflammation in diversion colitis
owing to SCFA deficiency [30]. In aged people, evidence
has been provided that reduction of butyrate levels is
depending on the decreased number of Faecalibacterium
(F.) prausnitzii, Eubacterium hallii and Eubacterium
rectal/Roseburia group [27]. Therefore, SCFA decrease
may lead to an impaired secretion of mucins by the IECs
and, therefore, easier entry of pathogens into the intestinal
mucosa, especially Enterobacteriaceae. These Gram-
negative bacteria are able to release lipopolysaccharides or
endotoxins, which, in turn, aggravate the inflammatory
condition [31]. In general terms, patients with IBD exhibit
an abnormal microbiota with instability of dominant
species which is higher than in healthy controls. In par-
ticular, F. Prausnitzii is severely reduced in Chron’s disease
and in ulcerative colitis with an increased prevalence of
adherent-invasive E. coli strains. However, the question is
still open whether this alteration of microbiota is the cause
or the consequence of IBD [32]. Moreover, evidence has
been provided for a decreased content of SCFA in colon
rectal cancer (CRC) with an increase of CRC in the west-
ern elderly population. A condition of chronic inflamma-
tion dependent on the change of microbiota leading toTLR-mediated NF-κB activation and colonization of the
bowel by toxigenic bacterial strains, such as Helicobacter
pylori, Bacteroides fragilis and Escherichia coli seems to
contribute to the pathogenesis of CRC [33]. In this frame-
work, in a recent study a comparison of aged microbiota
was made between community-dwelling individuals and
long-stay individuals. Actually, SCFA fecal content was
more pronounced in community group than in long-stay
patients [34]. In the latter, IL-6, IL-8 and C-reactive pro-
tein levels were higher than in the former group, as ex-
pression of a status of systemic inflammation. All these
evidences correlated to a change in microbiota since in
community individuals a higher numbers of Firmicutes
and lower numbers of Bacteroidetes than those observed
in long-stay patients were detected [34]. This situation is
depicted in Figure 3 where the activation of Th17 cells
leads to a condition of inflammation.
In this context, one should emphasize that obesity
leads to an alteration of intestinal microbiota with an in-
crease of Firmicutes [35], thus provoking a further ag-
gravation of inflamm-ageing.
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Nowadays, an arsenal of dietary products is available for
the restoration of microbiota in young and elderly popu-
lation [36]. Prebiotics, as non digestible components of
fruits, vegetables and grain, are oligosaccharides able to
accelerate the growth of gut anaerobes with production
of SCFA [29,37]. Probiotics are viable bacteria [38]
which enhance intestinal epithelial functions such as
production of mucus, defensins and sIgA [39]. Moreover,
probiotics upregulate phagocytic and natural killer (NK)
cell functions, also inducing activation of Treg cells
[40-42]. Probiotics and symbiotics (a mix of prebiotics
and probiotics) have been proven to be beneficial when
administered to aged people. For instance, supplementa-
tion of Bifidobacterium (B.) lactis HN 019 to aged indi-
viduals led to the recovery of granulocyte and NK cell
activities [43]. Oral intake of Lactobacillus (L.) pentosus
strain b240 (b240) has been shown to augment sIgA
secretion in elderly people. Moreover, b240 was able to
reduce frequency of common cold in aged individuals,
likely acting via mucosal immunity [44]. In a double-
blind trial B. lactis BL-01 and B. bifidum BB-02 along
with inulin as a prebiotic could increase numbers of
B. bifidum and total bifidobacteria and lactobacilli in
the microbiota of elderly subjects [45]. Modification of
microbiota seems to represent an essential event for less
frequency of winter infections to occur. In a recent trial,
administration for one month of fermented cow milk
containing L. rhamnosus and oligofructose (a symbiotic)
to free-living elderly increased serum levels of IL-1, IL-6,
and IL-8, while reduced basal levels of IL-12, IL-10 and
tumor necrosis factor (TNF)-α were not modified by this
treatment [46]. It is likely that induction of a more vigor-
ous acute phase response in these subjects may compen-
sate the impaired adaptive immune response in the case
of pathogen invasion.
Main functions of prebiotics and probiotics are repre-
sented in Figure 4.
Polyphenols, compounds widely present in the vegetal
kingdom, have been shown to influence the compositionFigure 4 Illustration of major activities of probiotics and prebiotics.of the gut microbiota. Consumption of blueberry [47],
grape juice [48] and red wine or gin [49], respectively,
mainly increased Bifidobacterium spp. in fecal samples
from human volunteers. In addition, our recent studies
have demonstrated that polyphenols contained in red wine
or in fermented grape marc exhibit an anti-inflammatory
role both in vitro [50] and in vivo [51]. Particularly,
in vitro induction of human Treg cells and in vitro attenu-
ation of colitis in mice with decrease of IL-1β and TNF-α
content in homogenized colon seem to sustain the anti-
inflammatory activities of polyphenols. Therefore, intake
of dietary polyphenols in the elderly may beneficially act
either on microbiota restoration and, consequentially, on
attenuation of chronic inflammatory conditions.
In this framework, deficiencies of micronutrients
(e.g., zinc) as well as vitamin B12 have been reported in
the elderly, thus accounting for frailty in the host [52,53].
However, the relationship between oligoelements and vita-
min B12 and intestinal microbiota deserves further inves-
tigation in elderly.
Conclusion
In conclusion, more studies are needed for a better com-
prehension of the interplay between human microbiota
and gut immune cells in elderly. In fact, inter individual
variations of microbiota composition mostly depending
on the type of diet, life style as well use of different
molecular techniques of bacterial identification seem to
represent the major difficulties in this area of research.
In this direction, in a very recent editorial Sartor [54]
has pointed out the emergence of certain strains of
sulphate-reducing Deltaprotobacteria, e.g., Bilophila (B.)
wadsworthia, which induces colitis in mice through
release of interferon-γ by Th1 cells. Quite interestingly,
B. wadsworthia is increased in patients with ulcerative
colitis, thus suggesting the need to identify new subsets
of patients with IBD using Deltaprotobacteria as bio-
markers [55]. It appears that consumption of saturated
milk fat led to expansion of B. wadsworthia in mice [55].
Therefore, the possibility that also in humans changes of
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be taken into consideration. On the other hand, in spite
of many advances in the field of mucosal immunity, age-
related changes, which occur at mucosal surface, are still
not completely explored. Most of the present knowledge
is related to studies in rodent models, while a few inves-
tigations have been conducted on the human aged mu-
cosal immunity. In order to overcome this problem the
use of humanized mice may help in the understanding
of mucosal immunity in elderly and, for instance,
constructing effective vaccines to combat infectious
diseases, as well as targeting specific components of the
intestinal microbiota with the supplementation of
nutraceuticals seem to represent the major therapeutic
intervention [56,57].
Abbreviations
APCs: Antigen presenting cells; b240: Lactobacillus pentosus strain b240;
CRC: Colon rectal cancer; DCs: Dendritic cells; GALT: Gut associated lymphoid
tissue; IECs: Intestinal epithelial cells; IL: Interleukin; IBD: Inflammatory bowel
disease; LP: Lamina propria; M: Microfolding cell; NK: Natural killer;
RA: Retinoic acid; SCFA: Short chain fatty acids; SFB: Segmented filamentous
bacteria; sIg: Secretory immunoglobulin; TGF: Transforming growth factor;
Th: T helper; TLR: Toll-like receptor; Treg: T regulatory; TNF: Tumor necrosis
factor.
Competing interests
Both authors declare that they have no competing interests.
Authors’ contributions
TM and EJ equally contributed. Both authors read and approved the final
manuscript.
Acknowledgements
Paper supported in part by an intramural grant (ex 60%) from the University
of Bari, Bari, (Italy).
Received: 23 November 2012 Accepted: 10 May 2013
Published: 5 August 2013
References
1. Moore WE, Holdeman LV: Human fecal flora: the normal flora of 20
Japanese-Hawaiians. Appl Microbiol 1974, 27:961–979.
2. Ley RE, Peterson DA, Gordon JI: Ecological and evolutionary forces
shaping microbial diversity in the human intestine. Cell 2006,
124:837–848.
3. Ouwehand A, Vesterlund S: Health aspects of probiotics. IDrugs 2003,
6:573–580.
4. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans
AD, de Vos WM: Mucosa-associated bacteria in the human
gastrointestinal tract are uniformly distributed along the colon and differ
from the community recovered from feces. Appl Environ Microbiol 2002,
68:3401–3407.
5. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill
SR, Nelson KE, Relman DA: Diversity of the human intestinal microbial
flora. Science 2005, 308:1635–1638.
6. Louis P, Scott KP, Duncan SH, Flint HJ: Understanding the effects of diet
on bacterial metabolism in the large intestine. J Appl Microbiol 2007,
102:1197–1208.
7. Miron N, Cristea V: Enterocytes: active cells in tolerance to food and
microbial antigens in the gut. Clin Exp Immunol 2012, 167:405–412.
doi:10.1111/j.1365-2249.2011.04523.x.
8. Kraehenbuhl JP, Neutra MR: Epithelial M cells: differentiation and function.
Annu Rev Cell Dev Biol 2000, 16:301–332.
9. Iwasaki A: Mucosal dendritic cells. Annu Rev Immunol 2007, 25:381–418.10. Kanai T, Mikami Y, Sujino T, Hisamatsu T, Hibi T: RORγt-dependent
IL-17A-producing cells in the pathogenesis of intestinal
inflammation. Mucosal Immunol 2012, 5:240–247. doi:10.1038/mi.2012.6.
11. Maldonado RA, von Andrian UH: How tolerogenic dendritic cells induce
regulatory T cells. Adv Immunol 2010, 108:111–165.
12. Hadis U, Wahl B, Schulz O, Hardtke-Wolenski M, Schippers A, Wagner N,
Müller W, Sparwasser T, Förster R, Pabst O: Intestinal tolerance requires gut
homing and expansion of FoxP3+ regulatory T cells in the lamina
propria. Immunity 2011, 34:237–246.
13. Agace WW, Persson EK: How vitamin A metabolizing dendritic cells are
generated in the gut mucosa. Trends Immunol 2012, 33:42–48.
14. Dicarlo AL, Fuldner R, Kaminski J, Hodes R: Aging in the context of
immunological architecture, function and disease outcomes. Trends
Immunol 2009, 30:293–294.
15. Biagi E, Candela M, Turroni S, Garagnani P, Franceschi C, Brigidi P: Ageing
and gut microbes: perspectives for health maintenance and longevity.
Pharmacol Res 2012. doi:10.1016/j.phrs.2012.10.005.
16. Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G: Aging of
the immune system as a prognostic factor for human longevity.
Physiology (Bethesda) 2008, 23:64–74.
17. Magrone T, Jirillo E: The interplay between the gut immune system and
microbiota in health and disease: nutraceutical intervention for restoring
intestinal homeostasis. Curr Pharm Des 2013, 9(7):1329–1342.
18. Round JL, Mazmanian SK: Inducible Foxp3+ regulatory T-cell
development by a commensal bacterium of the intestinal microbiota.
Proc Natl Acad Sci U S A 2010, 107:12204–12209.
19. Davies JM, Sheil B, Shanahan F: Bacterial signalling overrides cytokine
signalling and modifies dendritic cell differentiation. Immunology 2009,
128(Suppl 1):e805–e815.
20. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb
KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y,
Honda K, Littman DR: Induction of intestinal Th17 cells by segmented
filamentous bacteria. Cell 2009, 139:485–498.
21. Feng T, Wang L, Schoeb TR, Elson CO, Cong Y: Microbiota innate
stimulation is a prerequisite for T cell spontaneous proliferation and
induction of experimental colitis. J Exp Med 2010, 207:1321–1332.
doi:10.1084/jem.20092253.
22. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E,
Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van Sinderen D,
O'Connor M, Harnedy N, O'Connor K, Henry C, O'Mahony D, Fitzgerald AP,
Shanahan F, Twomey C, Hill C, Ross RP, O'Toole PW: Composition,
variability, and temporal stability of the intestinal microbiota of the
elderly. Proc Natl Acad Sci U S A 2011, 108(Suppl 1):4586–4591.
23. Hopkins MJ, Sharp R, Macfarlane GT: Age and disease related changes in
intestinal bacterial populations assessed by cell culture, 16S rRNA
abundance, and community cellular fatty acid profiles. Gut 2001, 48:198–205.
24. He T, Harmsen HJ, Raangs GC, Welling GW: Composition of faecal
microbiota of elderly people. Microb Ecol Health Dis 2003, 15:153–159.
25. Harmsen HJ, Wildeboer-Veloo AC, Grijpstra J, Knol J, Degener JE, Welling
GW: Development of 16S rRNA-based probes for the Coriobacterium
group and the Atopobium cluster and their application for enumeration
of Coriobacteriaceae in human feces from volunteers of different age
groups. Appl Environ Microbiol 2000, 66:4523–4527.
26. Tiihonen K, Ouwehand AC, Rautonen N: Human intestinal microbiota and
healthy ageing. Ageing Res Rev 2010, 9:107–116.
27. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkïla J, Monti D,
Satokari R, Franceschi C, Brigidi P, De Vos W: Through ageing, and beyond:
gut microbiota and inflammatory status in seniors and centenarians.
PLoS One 2010, 5:e10667.
28. Pédron T, Sansonetti P: Commensals, bacterial pathogens and intestinal
inflammation: an intriguing ménage à trois. Cell Host Microbe 2008, 3:344–
347.
29. De Vuyst L, Leroy F: Cross-feeding between bifidobacteria and butyrate-
producing colon bacteria explains bifdobacterial competitiveness,
butyrate production, and gas production. Int J Food Microbiol 2011,
149:73–80.
30. Ioannidis O, Varnalidis I, Paraskevas G, Botsios D: Nutritional modulation of
the inflammatory bowel response. Digestion 2011, 84:89–101.
31. Schiffrin EJ, Morley JE, Donnet-Hughes A, Guigoz Y: The inflammatory
status of the elderly: the intestinal contribution. Mutat Res 2010,
690:50–56.
Magrone and Jirillo Immunity & Ageing 2013, 10:31 Page 6 of 6
http://www.immunityageing.com/content/10/1/3132. Manichanh C, Borruel N, Casellas F, Guarner F: The gut microbiota in IBD.
Nat Rev Gastroenterol Hepatol 2012, 9:599–608. doi:10.1038/
nrgastro.2012.152.
33. Kraus S, Arber N: Inflammation and colorectal cancer. Curr Opin Pharmacol
2009, 9:405–410.
34. Kinross J, Nicholson JK: Gut microbiota: dietary and social modulation of
gut microbiota in the elderly. Nat Rev Gastroenterol Hepatol 2012,
9:563–564. doi:10.1038/nrgastro.2012.169.
35. Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Microbial ecology: Human gut
microbes associated with obesity. Nature 2006, 444:1022–1023.
doi:10.1038/4441022a.
36. Candore G, Caruso C, Jirillo E, Magrone T, Vasto S: Low grade inflammation
as a common pathogenetic denominator in age-related diseases: novel
drug targets for anti-ageing strategies and successful ageing
achievement. Curr Pharm Des 2010, 16:584–596.
37. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I,
Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K,
Coxam V, Davicco MJ, Léotoing L, Wittrant Y, Delzenne NM, Cani PD,
Neyrinck AM, Meheust A: Prebiotic effects: metabolic and health benefits.
Br J Nutr 2010, 104(Suppl 2):S1–S63.
38. Hume ME: Historic perspective: prebiotics, probiotics, and other
alternatives to antibiotics. Poult Sci 2011, 90:2663–2669.
39. Wallace TC, Guarner F, Madsen K, Cabana MD, Gibson G, Hentges E, Sanders
ME: Human gut microbiota and its relationship to health and disease.
Nutr Rev 2011, 69:392–403. doi:10.1111/j.1753-4887.2011.00402.x.
40. de LeBlanc AM, Castillo NA, Perdigon G: Anti-infective mechanisms
induced by a probiotic Lactobacillus strain against Salmonella enterica
serovar Typhimurium infection. Int J Food Microbiol 2010, 138:223–231.
41. Macpherson AJ, Slack E: The functional interactions of commensal
bacteria with intestinal secretory IgA. Curr Opin Gastroenterol 2007,
23:673–678.
42. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, Nam JH, Rhee JH,
Hwang KC, Im SH: Generation of regulatory dendritic cells and CD4 +
Foxp3+ T cells by probiotics administration suppresses immune
disorders. Proc Natl Acad Sci U S A 2010, 107:2159–2164.
43. Gill HS, Rutherfurd KJ, Cross ML, Gopal PK: Enhancement of immunity in
the elderly by dietary supplementation with the probiotic
Bifidobacterium lactis HN019. Am J Clin Nutr 2001, 74:833–839.
44. Shinkai S, Toba M, Saito T, Sato I, Tsubouchi M, Taira K, Kakumoto K,
Inamatsu T, Yoshida H, Fujiwara Y, Fukaya T, Matsumoto T, Tateda K,
Yamaguchi K, Kohda N, Kohno S: Immunoprotective effects of oral intake
of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a
randomised, double-blind, placebo-controlled trial. Br J Nutr 2012:1–10.
http://dx.doi.org/10.1017/S0007114512003753.
45. Bartosch S, Woodmansey EJ, Paterson JC, McMurdo ME, Macfarlane GT:
Microbiological effects of consuming a synbiotic containing
Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in
elderly persons, determined by real-time polymerase chain reaction and
counting of viable bacteria. Clin Infect Dis 2005, 40:28–37.
46. Amati L, Marzulli G, Martulli M, Pugliese V, Caruso C, Candore G, Vasto S,
Jirillo E: Administration of a synbiotic to free-living elderly and evaluation
of serum cytokines. A pilot study. Curr Pharm Des 2010, 16:854–858.
47. Vendrame S, Guglielmetti S, Riso P, Arioli S, Klimis-Zacas D, Porrini M: Six-
week consumption of a wild blueberry powder drink increases
bifidobacteria in the human gut. J Agric Food Chem 2011, 59:12815–12820.
48. Jacobs DM, Deltimple N, van Velzen E, van Dorsten FA, Bingham M,
Vaughan EE, van Duynhoven J: (1)H NMR metabolite profiling of feces as
a tool to assess the impact of nutrition on the human microbiome.
NMR Biomed 2008, 21:615–626.
49. Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, Gomez-Zumaquero JM,
Clemente-Postigo M, Estruch R, Cardona Diaz F, Andrés-Lacueva C,
Tinahones FJ: Influence of red wine polyphenols and ethanol on the gut
microbiota ecology and biochemical biomarkers. Am J Clin Nutr 2012,
95:1323–1334.
50. Magrone T, Marzulli G, Jirillo E: Immunopathogenesis of
neurodegenerative diseases: current therapeutic models of
neuroprotection with special reference to natural products. Curr Pharm
Des 2012, 18:34–42.
51. Kawaguchi K, Matsumoto T, Kumazawa Y: Effects of antioxidant
polyphenols on TNF-alpha-related diseases. Curr Top Med Chem 2011,
11:1767–1779.52. Mocchegiani E, Costarelli L, Giacconi R, Piacenza F, Basso A, Malavolta M:
Micronutrient (Zn, Cu, Fe)-gene interactions in ageing and inflammatory
age-related diseases: implications for treatments. Ageing Res Rev 2012,
11:297–319. doi:10.1016/j.arr.2012.01.004.
53. Dhonukshe-Rutten RA, Lips M, de Jong N, Chin A, Paw MJ, Hiddink GJ, van
Dusseldorp M, De Groot LC, van Staveren WA: Vitamin B-12 status is
associated with bone mineral content and bone mineral density in frail
elderly women but not in men. J Nutr 2003, 133:801–807.
54. Sartor RB: Gut microbiota: Diet promotes dysbiosis and colitis in
susceptible hosts. Nat Rev Gastroenterol Hepatol 2012, 9:561–562.
doi:10.1038/nrgastro.2012.157.
55. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A,
Antonopoulos DA, Jabri B, Chang EB: Dietary-fat-induced taurocholic acid
promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012,
487:104–108.
56. Fujihashi K, Kiyono H: Mucosal immunosenescence: new developments
and vaccines to control infectious diseases. Trends Immunol 2009,
30:334–343.
57. Rehman T: Role of the gut microbiota in age-related chronic
inflammation. Endocr Metab Immune Disord Drug Targets 2012,
12(4):361–367.
doi:10.1186/1742-4933-10-31
Cite this article as: Magrone and Jirillo: The interaction between gut
microbiota and age-related changes in immune function and
inflammation. Immunity & Ageing 2013 10:31.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
